What is Zacks Research's Forecast for Humana Q3 Earnings?

Key Points

• Analysts at Zacks Research have raised Humana's Q3 2025 earnings per share estimate from $1.68 to $2.51, reflecting a positive outlook for the insurance provider's performance.
• Humana reported Q2 earnings of $6.27 EPS, slightly missing the consensus estimate of $6.32, while achieving revenues of $32.39 billion, exceeding analyst expectations.
• The stock currently has an average rating of "Hold" among 24 analysts, with target prices ranging from $275.00 to $315.00.

Humana Inc. (NYSE:HUM - Free Report) - Equities researchers at Zacks Research lifted their Q3 2025 earnings estimates for Humana in a research report issued to clients and investors on Wednesday, August 13th. Zacks Research analyst Team now forecasts that the insurance provider will earn $2.51 per share for the quarter, up from their previous forecast of $1.68. The consensus estimate for Humana's current full-year earnings is $16.47 per share. Zacks Research also issued estimates for Humana's Q4 2025 earnings at ($3.36) EPS, Q1 2026 earnings at $7.30 EPS, Q2 2026 earnings at $4.43 EPS, Q3 2026 earnings at $1.83 EPS, Q4 2026 earnings at ($0.62) EPS, FY2026 earnings at $12.94 EPS, Q1 2027 earnings at $9.21 EPS and FY2027 earnings at $20.86 EPS.

HUM has been the subject of several other research reports. Bank of America reduced their target price on shares of Humana from $320.00 to $260.00 and set a "neutral" rating for the company in a research note on Tuesday, June 17th. Robert W. Baird lowered their price target on shares of Humana from $300.00 to $297.00 and set a "neutral" rating for the company in a report on Friday, July 25th. Barclays set a $275.00 target price on shares of Humana and gave the stock an "equal weight" rating in a research report on Thursday, July 31st. Oppenheimer raised their price target on shares of Humana from $300.00 to $310.00 and gave the company an "outperform" rating in a report on Thursday, May 1st. Finally, Piper Sandler dropped their price target on shares of Humana from $288.00 to $272.00 and set a "neutral" rating on the stock in a report on Thursday, July 31st. Seven equities research analysts have rated the stock with a Buy rating and sixteen have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $281.43.

Humana Stock Up 0.6%

Shares of HUM traded up $1.8540 during trading hours on Monday, reaching $290.1040. 1,241,131 shares of the stock traded hands, compared to its average volume of 1,726,279. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 0.69. The stock has a fifty day simple moving average of $244.92 and a 200 day simple moving average of $253.44. Humana has a 52 week low of $206.87 and a 52 week high of $382.72. The company has a market cap of $34.89 billion, a price-to-earnings ratio of 22.26, a PEG ratio of 1.69 and a beta of 0.44.

Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 EPS for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). Humana had a return on equity of 13.67% and a net margin of 1.28%.The company had revenue of $32.39 billion during the quarter, compared to analyst estimates of $31.85 billion. During the same quarter in the previous year, the business posted $6.96 earnings per share. The company's revenue for the quarter was up 9.6% compared to the same quarter last year. Humana has set its FY 2025 guidance at 17.000- EPS.

Institutional Investors Weigh In On Humana

A number of institutional investors have recently added to or reduced their stakes in HUM. Cary Street Partners Investment Advisory LLC grew its holdings in shares of Humana by 63.9% in the first quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider's stock valued at $31,000 after purchasing an additional 46 shares in the last quarter. Riverview Trust Co purchased a new position in shares of Humana in the first quarter valued at $34,000. Elevation Point Wealth Partners LLC purchased a new position in shares of Humana in the second quarter valued at $32,000. Garde Capital Inc. purchased a new position in shares of Humana in the first quarter valued at $36,000. Finally, Zions Bancorporation National Association UT purchased a new position in shares of Humana in the first quarter valued at $37,000. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.